Supernus Pharmaceuticals | SUPN - Operating Profit


Supernus Pharmaceuticals reported $-21.04M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Abbott USD 2.13B 281M Jun/2026
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Canopy Growth CAD -27.47M 14.81M Mar/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 23.5M 10.1M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Xeris Pharmaceuticals USD 7.92M 8.86M Mar/2026